Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

500 - Optimizing Outcomes Beyond Day +100: Process for Identifying and Managing High-Risk Allogeneic Transplant Recipients

Autor: Serafino, Sheila, Majhail, Navneet S., Curtis, Julie, Bernhard, Laura, Caroniti, Sharon, Sobecks, Ronald M., Elberson, Jamie, Hodgeman, Brittany, Starn, Jamie, Winslow, Victoria, Hamilton, Betty Ky

Publikováno v: In Biology of Blood and Marrow Transplantation March 2017 23(3) Supplement:S451-S452

Day 100 risk assessment tool predicts overall survival in allogeneic hematopoietic cell transplantation.

Autor: Hegde P; Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA., Rybicki L; Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA., Serafino S; Blood and Marrow Transplantation, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Ferraro C; Blood and Marrow Transplantation, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Kalaycio M; Blood and Marrow Transplantation, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Sobecks R; Blood and Marrow Transplantation, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Gerds AT; Blood and Marrow Transplantation, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Caroniti S; Blood and Marrow Transplantation, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Corrigan D; Blood and Marrow Transplantation, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Giannetti K; Blood and Marrow Transplantation, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Elberson J; Blood and Marrow Transplantation, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Hodgeman B; Blood and Marrow Transplantation, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Starn J; Blood and Marrow Transplantation, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Dabney J; Blood and Marrow Transplantation, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., McLellan L; Blood and Marrow Transplantation, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Majhail NS; Blood and Marrow Transplantation, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Hamilton BK; Blood and Marrow Transplantation, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. hamiltb2@ccf.org.

Publikováno v: Bone marrow transplantation [Bone Marrow Transplant] 2022 Jan; Vol. 57 (1), pp. 131-133. Date of Electronic Publication: 2021 Oct 09.